** Shares of gene therapy makers and developers slide premarket after WSJ and other media outlets report that Peter Marks, a top official at the US FDA, has been pushed out of the agency
** Marks was the head of FDA's Center for Biologics Evaluation and Research (CBER) and introduced several programs to accelerate the development of gene and cell therapies during his tenure
** Taysha Gene Therapies TSHA.O down 10.9% at $1.72 premarket, Solid Biosciences SLDB.O down 7.2% at $4.01, US-listed shares of CRISPR Therapeutics CRSP.O down 3.8% at $35.60
** "Gene and cell therapies likely under increased pressure, given CBER and Marks' intimate relationship with many of these companies and programs," says BMO Capital Markets analyst Evan Seigerman
** Marks did not respond to Reuters' request for comment
** Marks was given the choice by a Health and Human Services official to resign or be fired, according to WSJ, which also reported that his resignation is effective April 5
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。